The U.S. Centers for Disease Control and Prevention (CDC) has revised its guidance on COVID-19 vaccines for children, stating that vaccination for healthy individuals aged 6 months to 17 years should follow a “shared clinical decision-making” process. This means that shots are still available, but only if parents and doctors agree it's necessary based on individual circumstances.
The move marks a shift from earlier CDC guidance, which broadly recommended updated COVID-19 vaccines for everyone six months and older. The updated schedule, published Thursday, outlines that if parents want their child vaccinated, they may proceed based on a healthcare provider’s judgment and the family’s preference.
Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic, claimed earlier in the week that COVID vaccines for healthy children and pregnant women had been removed from the CDC’s immunization schedule. However, a Department of Health and Human Services spokesperson said there is no contradiction, as the CDC’s updated guidance no longer promotes universal vaccination for healthy children but still allows it case-by-case.
Medical experts criticized Kennedy’s unilateral announcement, saying it bypassed the CDC’s usual advisory process. The Infectious Diseases Society of America warned the change may limit access and insurance coverage, especially for vulnerable children. They emphasized that COVID-19 can cause serious illness in children, including long COVID symptoms that may impact development.
According to CDC data, nearly 1,900 children under 18 have died from COVID-19 in the U.S. as of 2023. Vaccine makers Pfizer, Moderna, and Novavax have not commented on the development.
The FDA also recently announced it would require new clinical trials for annual COVID boosters in healthy individuals under 65, reinforcing a more limited use strategy moving forward.


Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Trump Administration Halts Immigration, Green Card, and Citizenship Processing for 19 Countries
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
National Guard Member Killed in White House-Area Shooting Sparks Terror Probe and Immigration Review
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Germany Moves to Approve €2.9 Billion Defense Procurement Package
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Peru Moves to Declare State of Emergency at Chile Border as Migrant Tensions Rise
Australia Releases New National AI Plan, Opts for Existing Laws to Manage Risks 



